Found 2 results
Filters: Author is W.X. Ye  [Clear All Filters]
C. Q. Gan, Wang, X. Y., Cao, Y. D., Ye, W. X., Liu, H., and Sun, Y. Y., Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women, vol. 10, pp. 3514-3519, 2011.
Dixit V, Hariparsad N, Li F, Desai P, et al. (2007). Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35: 1853-1859. PMid:17639026   Economopoulos KP and Sergentanis TN (2010). Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis. Breast Cancer Res. Treat. 124: 293-294. PMid:20686834   Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, et al. (2008). Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet. Genomics 18: 515-523. PMid:18496131   Ercan B, Ayaz L, Cicek D and Tamer L (2008). Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem. Funct. 26: 309-313. PMid:17868191   Fava C, Montagnana M, Almgren P, Rosberg L, et al. (2008). The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 52: 373-380. PMid:18574070   Fichtlscherer S, Dimmeler S, Breuer S, Busse R, et al. (2004). Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 109: 178-183. PMid:14662709   Gauthier KM, Falck JR, Reddy LM and Campbell WB (2004). 14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol. Res. 49: 515-524. PMid:15026029   Goetz M and Suman V (2010). Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 116: 1007. PMid:20041480   González-Tejera G, Gaedigk A and Corey S (2010). Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients. P. R. Health Sci. J. 29: 299-304. PMid:20799519   Imig JD (2000). Epoxygenase metabolites. Epithelial and vascular actions. Mol. Biotechnol. 16: 233-251.   Jernström H, Bageman E, Rose C, Jonsson PE, et al. (2009). CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br. J. Cancer 101: 1817-1823. PMid:19935798 PMCid:2788256   Jiang JG, Chen CL, Card JW, Yang S, et al. (2005). Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 65: 4707. PMid:15930289   Jiang JG, Ning YG, Chen C, Ma D, et al. (2007). Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 67: 6665-6674. PMid:17638876   Jiang JG, Fu XN, Chen CL and Wang DW (2009). Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines. Ai Zheng. 28: 93-96. PMid:19550113   Justenhoven C, Hamann U, Pierl CB, Baisch C, et al. (2009). CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res. Treat. 115: 391-396. PMid:18521743   Knüpfer H, Schmidt R, Stanitz D, Brauckhoff M, et al. (2004). CYP2C and IL-6 expression in breast cancer. Breast 13: 28-34. PMid:14759713   Lundell K and Wikvall K (2008). Species-specific and age-dependent bile acid composition: aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr. Drug Metab. 9: 323-331. PMid:18473750   Node K, Ruan XL, Dai J, Yang SX, et al. (2001). Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J. Biol. Chem. 276: 15983-15989. PMid:11279071   Ozbek YK, Ozturk T, Tuzuner BM, Calay Z, et al. (2010). Combined effect of CYP1B1 codon 432 polymorphism and N-acetyltransferase 2 slow acetylator phenotypes in relation to breast cancer in the Turkish population. Anticancer Res. 30: 2885-2889. PMid:20683028   Ruiter R, Bijl MJ, van Schaik RH, Berns EM, et al. (2010). CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 11: 1367-1375. PMid:21047200   Stingl JC, Parmar S, Huber-Wechselberger A, Kainz A, et al. (2010). Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr. Med. Res. Opin. 26: 2535-2542. PMid:20849243   Sun J, Sui X, Bradbury JA, Zeldin DC, et al. (2002). Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 90: 1020-1027. PMid:12016269   Thompson AM, Johnson A, Quinlan P, Hillman G, et al. (2011). Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 125: 279-287. PMid:20809362